September 20, 2014 7:31 PM ET

Biotechnology

Company Overview of Palatin Technologies Inc.

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has completed Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD). Its drug development programs include Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Next Generation Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; and PL-3994, a natriuretic peptide receptor-A agonist that has completed Phase I clinical trial for t...

4B Cedar Brook Drive

Cranbury, NJ 08512

United States

Founded in 1986

17 Employees

Phone:

609-495-2200

Fax:

609-495-2201

Key Executives for Palatin Technologies Inc.

Co-Founder
Age: 52
Total Annual Compensation: $450.0K
Chief Financial Officer
Age: 57
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.

Palatin Technologies Inc. Key Developments

Palatin Technologies, Inc Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2014

Palatin Technologies Inc. reported earnings results for the fourth quarter and full year ended June 30, 2014. For the quarter, the company reported net loss was $4.32 million, or $0.04 loss per share, compared to a net loss of $4.72 million, or $0.04 loss per share, for the same quarter ended June 30, 2013. Loss from operations for the fourth quarter ended June 30, 2014 was $4.32 million, compared to a loss from operations of $4.72 million for the same quarter ended June 30, 2013. Net loss for the year ended June 30, 2014 was $13.93 million, or $0.13 loss per share, compared to a net loss of $20.86 million, or $0.21 loss per share, for the same period ended June 30, 2013. Loss from operations for the year ended June 30, 2014 was $15.79 million, compared to a loss from operations of $15.58 million for the same period ended June 30, 2013.

Palatin Technologies Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended June 30, 2014

Palatin Technologies Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended June 30, 2014. For the quarter, the company's loss from operations was $4.3 million compared with $4.7 million a year ago. Loss before income taxes was $4.3 million compared with $4.7 million a year ago. Net loss was $4.3 million or $0.04 per basic and diluted share compared with $4.7 million or $0.04 per basic and diluted share a year ago. The decrease in net loss for the quarter ended June 30, 2014 compared to the net loss for the quarter ended June 30, 2013 was the result of a decrease in operating expenses primarily related to its bremelanotide for female sexual dysfunction program. For the year, the company's loss from operations was $15.8 million compared with $15.6 million a year ago. Loss before income taxes was $15.8 million compared with $22.6 million a year ago. Net loss was $13.9 million or $0.13 per basic and diluted share compared with $20.9 million or $0.21 per basic and diluted share a year ago. The decrease in net loss for the year ended June 30, 2014, compared to the net loss for the year ended June 30, 2013 was mainly attributable to the recognition of a $7.1 million, non-cash charge to expense for the increase in fair value of warrants related to its July 3, 2012 private placement offering.

Palatin Technologies Inc., Q4 2014 Earnings Call, Sep 09, 2014

Palatin Technologies Inc., Q4 2014 Earnings Call, Sep 09, 2014

Similar Private Companies By Industry

Company Name Region
Apellis Pharmaceuticals, Inc. United States
FibroGen, Inc. United States
CureDM, Inc. United States
Excelimmune, Inc. United States
Integrated BioTherapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Palatin Technologies Inc., please visit www.palatin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.